Skip to Content
 

VICC toll-free number 1-877-936-8422

Clinical Trials for PF-02341066

4 Open Trials

    Trial Type Protocol No. &
    Open Date
    Summary

    Treatment

    VICCTHO15129

    06/07/2016

    XALT3: Phase 3 Randomized Study Comparing X-396 to Crizotinib in Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC) Patients

    Treatment

    ECOGTHOE4512

    09/15/2015

    A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein

    Treatment

    ECOGEAY131-M

    07/16/2015

    Molecular Analysis for Therapy Choice

    Treatment

    COGANHL12P1

    10/20/2014

    A Randomized Phase II Trial of Brentuximab Vedotin (SGN35, NSC# 749710), or Crizotinib (NSC#749005, commercially labeled) in Combination with Chemotherapy for Newly Diagnosed Patients with Anaplastic Large Cell Lymphoma (ALCL) IND # 117117


    Print this page for your doctor